TY - JOUR
T1 - Scoping review of measures of treatment burden in patients with multimorbidity
T2 - advancements and current gaps
AU - Mendoza-Quispe, Daniel
AU - Perez-Leon, Silvana
AU - Alarcon-Ruiz, Christoper A.
AU - Gaspar, Andrea
AU - Cuba-Fuentes, María Sofía
AU - Zunt, Joseph R.
AU - Montori, Victor M.
AU - Bazo-Alvarez, Juan Carlos
AU - Miranda, J. Jaime
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/7
Y1 - 2023/7
N2 - Objectives: To identify, assess, and summarize the measures to assess burden of treatment in patients with multimorbidity (BoT-MMs) and their measurement properties. Study Design and Setting: MEDLINE via PubMed was searched from inception until May 2021. Independent reviewers extracted data from studies in which BoT-MMs were developed, validated, or reported as used, including an assessment of their measurement properties (e.g., validity and reliability) using the COnsensus-based Standards for the selection of health Measurement INstruments. Results: Eight BoT-MMs were identified across 72 studies. Most studies were performed in English (68%), in high-income countries (90%), without noting urban-rural settings (90%). No BoT-MMs had both sufficient content validity and internal consistency; some measurement properties were either insufficient or uncertain (e.g., responsiveness). Other frequent limitations of BoT-MMs included absent recall time, presence of floor effects, and unclear rationale for categorizing and interpreting raw scores. Conclusion: The evidence needed for use of extant BoT-MMs in patients with multimorbidity remains insufficiently developed, including that of suitability for their development, measurement properties, interpretability of scores, and use in low-resource settings. This review summarizes this evidence and identifies issues needing attention for using BoT-MMs in research and clinical practice.
AB - Objectives: To identify, assess, and summarize the measures to assess burden of treatment in patients with multimorbidity (BoT-MMs) and their measurement properties. Study Design and Setting: MEDLINE via PubMed was searched from inception until May 2021. Independent reviewers extracted data from studies in which BoT-MMs were developed, validated, or reported as used, including an assessment of their measurement properties (e.g., validity and reliability) using the COnsensus-based Standards for the selection of health Measurement INstruments. Results: Eight BoT-MMs were identified across 72 studies. Most studies were performed in English (68%), in high-income countries (90%), without noting urban-rural settings (90%). No BoT-MMs had both sufficient content validity and internal consistency; some measurement properties were either insufficient or uncertain (e.g., responsiveness). Other frequent limitations of BoT-MMs included absent recall time, presence of floor effects, and unclear rationale for categorizing and interpreting raw scores. Conclusion: The evidence needed for use of extant BoT-MMs in patients with multimorbidity remains insufficiently developed, including that of suitability for their development, measurement properties, interpretability of scores, and use in low-resource settings. This review summarizes this evidence and identifies issues needing attention for using BoT-MMs in research and clinical practice.
KW - Chronic disease
KW - Cost of illness
KW - Multimorbidity
KW - Patient-reported outcome measures
KW - Scoping review
KW - Surveys and questionnaires
UR - http://www.scopus.com/inward/record.url?scp=85162181479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162181479&partnerID=8YFLogxK
U2 - 10.1016/j.jclinepi.2023.05.013
DO - 10.1016/j.jclinepi.2023.05.013
M3 - Review article
C2 - 37217106
AN - SCOPUS:85162181479
SN - 0895-4356
VL - 159
SP - 92
EP - 105
JO - Journal of Clinical Epidemiology
JF - Journal of Clinical Epidemiology
ER -